Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01173471 · ClinicalTrials.gov registry record · Phase 2
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01173471 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 50 participants.
The verdict
NCT01173471, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of systemically administered AZD4017, compared with placebo, over a 28-day period in patients with raised intra-ocular pressure (IOP).
Interventions
- DRUG Placebo
- DRUG AZD4017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01173471
The ClinicalTrials.gov registry entry for NCT01173471 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01173471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01173471 about?
NCT01173471 is a clinical study titled "A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure". The purpose of this study is to evaluate the efficacy of systemically administered AZD4017, compared with placebo, over a 28-day period in patients with raised intra-ocular pressure (IOP).
What is the current status of trial NCT01173471?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2010-12. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01173471?
The interventions under investigation include: Placebo (DRUG), AZD4017 (DRUG).
Who is sponsoring clinical trial NCT01173471?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.